Render Target: SSR
Render Timestamp: 2024-11-17T17:44:29.776Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-04-05 20:35:03.144
Product last modified at: 2024-05-30T07:07:14.284Z
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Human Epigen #5493

Inquiry Info. # 5493

Please see our recommended alternatives.

    Product Information

    Formulation

    With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hEpigen. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.

    Storage

    Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
    Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

    Product Description

    MW (kDa) 8
    Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hEpigen. All lots are greater than 98% pure.
    Endotoxin Less than 0.01 ng endotoxin/1 μg hEpigen.
    Activity The bioactivity of recombinant hEpigen was determined in a MCF-10A cell proliferation assay. The ED50 of each lot is between 2-30 ng/ml.
    Molecular Formula Recombinant hEpigen does not have a Met on the amino terminus and has a calculated MW of 9,087. DTT-reduced and non-reduced protein migrate as 8 kDa polypeptides with non-reduced protein having slightly greater mobility due to intramolecular cystines. The expected amino-terminal AVTVT of recombinant hEpigen was verified by amino acid sequencing.

    Source / Purification

    Recombinant human Epigen (hEpigen) Ala24-Ala104 (Accession #Q6UW88-1) was produced in E. coli at Cell Signaling Technology.

    Background

    Epigen was identified as an EGF family member by amino acid sequence homology (1). The sequence was obtained from mouse keratinocyte mRNA. Epigen is expressed in normal human mammary tissue and in some prostate and breast carcinomas (2). Epigen binding to known EGF receptors is with lower affinity when compared to EGF. However, Epigen appears to be superior in inducing cell proliferation (2). Epigen induces responses in MDA-MB-468 breast carcinoma cells. Epigen also has effects on prostate cells and vascular endothelial cells (2). Epigen binds to ErbB1/Her1 (2). Binding causes receptor homodimerization and heterodimerization with other Erb/Her receptors (2).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.